Encouragingly, SKLB325 could significantly suppress the tumor‐derived VEGF levels in the circulation of mice and inhibit the expressions of CD34 and CD105 in renal cell orthotopic models, which were both the angiogenesis and proliferation markers. Here, CD34 is linked to neoplasm.